Literature DB >> 1155997

The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use.

N M Mattock, W Peters.   

Abstract

A variety of compounds used in the treatment of parasitic or bacterial infections in man, including leishmaniasis itself, were examined for their activity against three lines of Leishmania in tissue culture. The organisms used were L. mexicana mexicana, L. tropical major and L. donovani; they were grown in dog sarcoma and hamster peritoneal exudate cell lines. Leishmanicidal activity was observed in a number of compounds currently in clinical use for the treatment of one or other form of leishmaniasis. Cycloguanil, nifurtimox, amphotericin B and monomycin were effective but pentamidine showed poor activity. In each case marked differences were observed in the level of response in the different parasite lines. Organic antimonials were most active when anmastigotes were exposed to them prior to entry of the parasites into host cells. This suggests that such compounds may exert an effect on amastigotes during their brief extracellular transit from one host cell to another in vivo. A number of antimalarials showed good to moderate leishmanicidal action, particularly against L. mexicana and L.t. major. Several schistosomicidal agents also possessed leishmanicidal properties. The commonly used broad spectrum antibiotics showed little if any activity. In discusssion a comparison is drawn between data published on the action of some of these drugs against L.t. major in mice and our observations with the same strain and L. mexicana in tissue culture. A remarkably good agreement is found for most of the compounds examined. General agreement is also noted between these data and reports of clinical trials although it is not possible to draw too many conclusions because of the failure in most clinical studies to make an accurate identification of the causative Leishmania. It is concluded that, although the tissue culture model is not to be considered as ideal and can probably be improved, data obtained by its use do bear relevance to the action compounds in vivo, and the model may be use in the screening of drugs for leishmanicidal activity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155997

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  6 in total

1.  Use of in vitro method to assess different brands of anti-leishmanial drugs.

Authors:  S K Arora; R Sinha; S Sehgal
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

2.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Characterization of mitochondrial bioenergetic functions between two forms of Leishmania donovani - a comparative analysis.

Authors:  Subhasish Mondal; Jay Jyoti Roy; Tanmoy Bera
Journal:  J Bioenerg Biomembr       Date:  2014-08-10       Impact factor: 2.945

4.  In vitro activity of sulfonamides and sulfones against Leishmania major promastigotes.

Authors:  M P Peixoto; S M Beverley
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

5.  Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.

Authors:  Maiara Maria Romanelli; Thais Alves da Costa-Silva; Edezio Cunha-Junior; Daiane Dias Ferreira; Juliana M Guerra; Andres Jimenez Galisteo; Erika Gracielle Pinto; Leandro R S Barbosa; Eduardo Caio Torres-Santos; Andre Gustavo Tempone
Journal:  Front Cell Infect Microbiol       Date:  2019-10-29       Impact factor: 5.293

6.  Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.

Authors:  D Sereno; M Cavaleyra; K Zemzoumi; S Maquaire; A Ouaissi; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.